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Abstract
Acute respiratory distress syndrome is a major cause of respiratory failure in critically ill patients. 
Despite extensive research into its pathophysiology, mortality remains high. No effective 
pharmacotherapy exists. Based largely on numerous preclinical animal studies, administration of 
mesenchymal stem or stromal cell (MSC) as a therapeutic for acute lung injury holds great 
promise, and phase I/II clinical trials are currently underway internationally. However, concern for 
the use of stem cells, specifically the risk of iatrogenic tumor formation, as well as the prohibitive 
cost of production, storage, and distribution of cells in bone marrow transplant facilities may limit 
access to this life saving therapy. Accumulating evidence now suggest that novel stem cell derived 
therapies including MSC conditioned medium and extracellular vesicles released from MSCs, 
might constitute compelling alternatives. The current review summarizes the preclinical studies 
testing MSC extracellular vesicles as treatment for acute lung injury and other inflammatory lung 
diseases. While certain logistical obstacles limit the clinical applications of MSC conditioned 
medium such as the volume required for treatment and lack of standardization of what constitutes 
the components of conditioned medium, the therapeutic application of MSC extracellular vesicles 
remains promising, primarily due to ability of extracellular vesicles to maintain the functional 
phenotype of the parent cell. However, utilization of MSC extracellular vesicles will require large-
scale production and standardization concerning identification, characterization and quantification.
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INTRODUCTION
Acute respiratory distress syndrome (ARDS), the clinical manifestation of acute lung injury 
(ALI), is a major cause of acute respiratory failure where mortality remains as high as 33–
48% in critically ill patients.1,2 The most common triggering event for ARDS is severe 
Address correspondence to:, Jae-Woo Lee, MD, University of California San Francisco, Department of Anesthesiology, 505 Parnassus 
Ave., Box 0648, San Francisco, CA 94143, Telephone:(415) 476-0452, Fax:(415) 514-2999, leejw@anesthesia.ucsf.edu. 
Conflicts of Interests: None.
HHS Public Access
Author manuscript
Transfusion. Author manuscript; available in PMC 2019 February 09.
Published in final edited form as:
Transfusion. 2019 February ; 59(Suppl 1): 876–883. doi:10.1111/trf.14838.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
sepsis from either a pulmonary or non-pulmonary source, accounting for 79% of the cases.1 
However, various other inciting events including aspiration, toxic inhalation, lung contusion, 
acute pancreatitis, trauma, transfusion, burn injury, and cardiopulmonary bypass surgery can 
cause ARDS.3 Once triggered by infectious, chemical, or mechanical insult, the 
pathophysiology of ARDS results from complex interaction between the immune system 
and the alveolar-capillary barrier. Acute inflammatory response following the insult affects 
endothelial and epithelial type I/II cells in the alveoli. Damage to alveolar endothelium and 
epithelium directly increase the permeability of the alveolar-capillary barrier, and damage to 
type II cell impair pulmonary surfactant secretion and alveolar fluid clearance. The 
increased permeability of the alveolar-capillary barrier and impaired alveolar clearance 
result in pulmonary edema, which eventually cause impaired gas exchange and hypoxemia.4 
Currently, there is no available pharmacotherapy based on the pathophysiology of ARDS. 
The therapeutic options are limited to primarily supportive measures such as lung-protective 
ventilation, fluid conservative strategy, and prone positioning.5–8
Recently, mesenchymal stem cells (MSC) have been regarded as a promising approach for 
ARDS because of their ability to attenuate the major pathologies underlying ALI. MSC are 
non-hematopoietic precursor cells from a variety of tissues in adult such as the bone marrow, 
adipose tissue, and placenta. MSC were first described as fibroblast-like cells of the bone 
marrow in 1968.9 The definition of MSC was established by the International Society of 
Cellular Therapy in 2006 as the following criteria: 1) adherence to plastic: MSC must be 
adherent to plastic under standard tissue culture conditions; 2) specific surface antigens: 
MSC must express certain cell surface markers such as CD105, CD90 and CD73, but must 
not express CD45, CD34, CD14 or CD11b, CD79a, CD19 or HLA-DR; 3) and multipotent 
differentiation: MSC must be able to differentiate into osteoblasts, adipocytes and 
chondroblasts under standard in vitro conditions.10 The therapeutic effects of MSC were 
initially thought to derive from their engraftment in the injury site and regeneration. 
However, the presence of MSC in the injured organ is only transient, and the replacement of 
the damaged tissues with transdifferentiated stem cells is very limited (<5%).11,12 Current 
view is that therapeutic properties of MSC are derived from soluble factors with paracrine or 
endocrine effects.13–15 The soluble factors include growth factors, anti-inflammatory 
cytokines, and antimicrobial peptides, which can stabilize the alveolar-capillary barrier, 
enhance alveolar fluid clearance, and decrease infection.16 Recent studies have also 
underscored the new potential role of extracellular vesicles (EV), small anuclear membrane 
bound particles released from MSC, as a paracrine or endocrine vehicle to deliver various 
soluble factors with a similar phenotype as the parent cell.17–21 Although the preclinical 
studies for the therapeutic use of MSC derived EVs in ARDS is still in its infancy, its 
potential as treatment vs. using intact live cells are significant such as: 1) ability to store EVs 
without the use preservatives such as DMSO; 2) no need for a bone marrow transplant 
facility to store living cells, potentially increasing the number of facilities which can deliver 
stem cell derived therapy; 3) and potential ability to give multiple doses without significantly 
effecting the patient’s hemodynamic or respiratory parameters. In the current review, we 
summarize the biological basis and the preclinical data available for the potential use of 
MSC-derived EV for ALI.
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DEFINITION AND CHARACTERIZATION OF EXTRACELLULAR VESICLES
EVs are anuclear, membrane bound vesicles that are released by most cell types into the 
extracellular space. EVs may be secreted constitutively or following cell stimulation by 
soluble agonists, physical or chemical injury such as the oxidative stress and hypoxia, or 
shear stress.22 Although once considered cellular debris or as artifacts, EVs play an 
important role in intercellular communication by transporting various cargoes including 
proteins, RNAs, DNAs, and lipids between cells at both a paracrine and endocrine level.
23–28
 As EV transports complex biological information from donor cells to recipient cells, it 
can contribute to the maintenance of normal and pathophysiological conditions.25,29 EVs 
can be classified into exosomes, microvesicles, or apoptotic bodies according to size, 
biogenesis, and composition.30–32 Because there is no consensus on the nomenclature for 
the type of vesicles, especially for the microvesicles, other names such as shedding vesicles, 
ectosomes, exosome-like vesicles, nanoparticles, microparticles, and oncosomes have been 
employed in the literature. Microvesicles are generally heterogeneous in size ranging from 
50 to 1000 nm in diameter depending on the state of the cell during release. Whereas, 
exosomes are relatively homogenous in size with a diameter ranging from 40 to 200 nm. 
Furthermore, the process of vesicle formation and release from cells also differs between 
exosomes and microvesicles. Microvesicles are released by direct shedding or budding from 
the plasma membrane. Whereas, exosomes are assembled through an invagination process of 
the endosomal membrane of multi-vesicular bodies (MVBs) within cells and, then, the 
fusion of the MVBs with the plasma membrane resulting in its release.32 Due to the 
difference in assembly and release, each of the EV subtypes has its own characteristic 
surface and intracellular markers.33 The release of exosomes is often detected within 
minutes after stimulation while microvesicles are released within seconds after stimulation. 
Although there can be some uncertainty or overlap for EV subtype markers, CD63 and 
CD61 are known as common stereotypic markers for exosomes, and TyA and C1q for 
microvesicles. However, despite such differences, both of the two EV subtypes are released 
upon physiological or pathological stimulus and have important effects on cell physiology 
and pathology by transferring their cargoes to target cells over short or long distances. Some 
EVs can break down shortly after release and excrete their contents to the extracellular 
space. The released agents bind their receptors in adjacent cells and provoke rapid responses.
34–36
 Most EVs that maintain their structure longer can travel to target cells, and thus EVs 
can be found in major body fluids, such as blood, lymph, and cerebrospinal fluid.33 There 
are various patterns of the interaction between EVs and the target cells; 1) Direct stimulation 
to target cell through surface-expressed ligands; 2) Direct fusion to target cell transferring 
membrane receptor and luminal material; 3) And uptake of entire EVs by target cell in the 
endocytosis process 22,33. The interactions enable EVs to directly stimulate or transfer 
various materials including proteins and genetic information to target cells.
MSCs also secrete EVs, and the MSC-derived EVs have been shown to be as effective as 
MSCs in accelerating recovery in various injury models37 by transferring their content to 
recipient cells, resulting in a therapeutic effect. In ALI models, various therapeutic agents 
including keratinocyte growth factor (KGF), angiopoietin-1 (Ang-1), cyclooxygenase 2, and 
mitochondria have been identified. Because there are no standardized methods for isolation, 
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quantification and characterization of EVs, or differentiating MVs and exosomes, it is 
difficult to compare and analyze studies with MSC-derived EVs in terms of dose, route, and 
efficacy. However, in most studies involving MSC-derived EVs in ALI, EVs were isolated 
by ultracentrifugation at speeds of approximately 100,000 × g, and differential 
centrifugation or size columns were used to differentiate EVs into microvesicles and 
exosomes. In this review, we will use MSC-derived EVs as an umbrella term to include both 
microvesicles and exosomes.
While most studies have demonstrated the direct inhibition of inflammatory effector cells by 
MSCs, MSC can also have differential immunomodulatory effects, or even cause an 
inflammatory response, based largely by environmental cues. Depending on the level of 
inflammatory cytokines such as IFN-γ, IL-1ß, and TNFα, MSC can enhance the 
differentiation of naïve T cells into immunosuppressive Treg cells or pro-inflammatory Th17 
cells, and can cause an increase or decrease of T cell proliferation.38 Furthermore, MSCs 
monitor their environment and recognize danger signals through various toll like receptors 
(TLR). The stimulation of different TLRs result in different phenotypes of MSCs, with 
TLR3-treated MSC having increased immunomodulatory potential, whereas TLR4 
stimulation accelerating the pro-inflammatory response.39,40 Therefore, pre-treatment of 
MSC with inflammatory cytokines or TLR3 agonist can enhance the therapeutic effects in 
inflammatory disease models.41–44 The content and the therapeutic efficacy of MSC-derived 
EV can be differentiated according to the parental MSC phenotype. A recent study 
demonstrated that MSC pre-treated with IL-1β have greater immunomodulatory effects than 
naïve MSC by increasing microRNA-146a content in the MSC-derived EVs in a sepsis 
model.45 Another study using an ALI model showed that EV collected from pre-treated 
MSC with TLR3 agonist demonstrated increased antimicrobial effects than naïve MSC 
derived EV.46 Therefore, targeted pre-stimulation of MSC can be an efficient strategy to 
generate EVs with high therapeutic potential.
THERAPEUTIC USE OF MSC DERIVED EXTRACELLULAR VESICLES IN ALI 
MODELS
Cellular administration of MSCs as a therapeutic in preclinical models of ALI is very 
promising, and several phase 1/2 clinical trials with the use of MSCs in ARDS and/or sepsis 
are underway (such as NCT02097641 or NCT02421484). The biological rationale for the 
use of MSC in ALI include anti-inflammation on host tissue, reduction of the permeability 
of alveolar epithelium and endothelium, improvement of alveolar fluid clearance, 
enhancement of macrophage phagocytosis, and tissue repair through direct mitochondrial 
transfer with host cells.47,48 Similar to MSCs, the early pre-clinical studies using MSC-
derived EV in several ALI models are promising and discussed below (Figure).
1) Endotoxin-induced ALI
Zhu et al. demonstrated the therapeutic efficacy and mechanism of human MSC-derived EV 
in a mice ALI model induced by intra-tracheal administration of E.coli endotoxin.21 In the 
study, MSC-derived EV reduced alveolar inflammation and edema by decreasing the influx 
of inflammatory cells and total protein levels in the endotoxin-damaged alveolus. In 
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addition, the therapeutic effects of the EV were comparable regardless of route of 
administration, intra-tracheal or intravenous. Elimination of KGF activity found in the EVs 
using either siRNA or KGF antibody partially abrogated the therapeutic effects of MSC-
derived EV, which suggested that the transfer of KGF mRNA to the target tissue was one of 
mechanisms of action. KGF, also known as FGF7, is an epithelial specific growth factor and 
a major paracrine factor released from MSCs with significant reparative properties. In ALI 
models, KGF from MSC has been shown to restore protein permeability and increase fluid 
clearance in the alveolus following injury.47,48
A recent study by Tang et al.49 also demonstrated MSC-derived EVs as a therapeutic agent 
in endotoxin-induced ALI in mice. Intra-tracheal administration of MSC EVs ameliorated 
lung inflammation and restored alveolar-capillary permeability after endotoxin induced 
injury. Furthermore, administration of the EVs suppressed TNFα and increased IL-10 
secretion in a mouse macrophage cell line (RAW264.7) following endotoxin stimulation. 
Administration of EVs from Ang-1 SiRNA transfected MSCs partly abrogated the beneficial 
effects on alveolar inflammation and permeability in mice as well as immunomodulation in 
macrophages. Ang-1 is an angiogenic factor that stabilizes endothelial cells during injury, 
reduces endothelial permeability, and suppresses leukocyte-endothelium interactions. Ang-1 
is also significantly secreted by MSCs.47,48
Recently, Morrison et al.50 demonstrated that MSC-derived EV protected against endotoxin-
induced ALI by altering alveolar macrophage towards an anti-inflammatory phenotype with 
enhance phagocytic activity via EV-mediated mitochondrial transfer. Intra-tracheal 
administration of alveolar macrophages pre-treated with MSC-derived EV reduced 
inflammatory cells recruitment and the levels of TNFα and protein in the alveolus of mice 
with endotoxin-induced lung injury. Previously, using MSC as a therapeutic to prevent 
silica-induced lung inflammation and fibrosis, Phinney et al.51 also found that MSCs shed 
exosomes that modulated toll-like receptor signaling and cytokine secretion in macrophages, 
in part, by transfer of regulatory microRNAs; miR-451, known to suppress TNF and 
macrophage migration inhibitory factor, was highly abundant in MSC-derived exosomes, 
suggesting that the possible transfer of miR-451 to and increased expression in macrophages 
inhibited TNF secretion in response to silica. The authors also demonstrated that MSC-
derived exosomes prevented the recruitment of Ly6Chi monocytes and reduced secretion of 
pro-fibrotic IL-10 and TGFβ by these cells. Lastly, the author found that MSCs managed 
intracellular oxidative stress by the transfer of depolarized mitochondria by MSCs. MSC-
derived vesicles containing the mitochondria were engulfed and re-utilized by macrophages, 
resulting in enhanced bioenergetics. These two studies demonstrated that mitochondrial 
transfer by MSC-derived EVs was a significant mechanism for its therapeutic effect. It was 
already known that MSC was able to transfer mitochondria to the alveolar epithelium52 and 
macrophage53 through direct cell contact via tunneling nanotubes, but, now, MSC-derived 
EVs was also able to transfer mitochondria to recipient cells.
2) Bacteria-induced ALI
Monsel et al.46 instilled live E.coli bacteria into trachea, which caused bacterial pneumonia 
and lung injury, in order to demonstrate the therapeutic effect of MSC-derived EV on 
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bacteria-induced ALI. The authors demonstrated that intravenous administration of MSC-
derived MVs improved survival and reduced the bacterial load, inflammation, and protein 
permeability in the injured alveolus with live E.coli. The therapeutic effects were mediated 
in part by KGF. More specifically, MSC-derived EV increased the phagocytosis of bacteria 
and suppressed TNFα secretion in monocytes stimulated with bacteria. MSC-derived EV 
also restored intracellular ATP levels in injured alveolar epithelial type II cells. These results 
confirmed that the mechanisms of MSC-derived EV are as variable as those of MSCs 
including anti-inflammatory, anti-microbial, and with direct metabolomic effects. 
Furthermore, the EVs isolated from pre-stimulated MSC with TLR3 agonist further 
increased phagocytosis, decreased TNFα secretion, increased IL-10 secretion in monocytes 
compared to naïve MSC-derived EVs in mice with bacteria-induced ALI, suggesting that the 
contents and effects of the MSC-derived EVs can be modified by changing the phenotype of 
the parent cell. Lastly, Monsel et al. also found that the surface receptor CD44 was crucial 
for incorporation of MSC-derived EVs into injured monocytes and alveolar epithelial type 2 
cells. CD44 is the principal surface receptor for hyaluronic acid, a major extracellular matrix 
component.54 It is expressed in almost every cell type including MSC, and associated with 
the regulation of cell proliferation, differentiation, survival, migration, and trafficking to 
tissues. CD44 is essential for the migration of MSC into the extracellular matrix.55 CD44 on 
the surface of MSC-derived EV appears to be important for in the incorporation into injured 
tissues, which is critical step for the therapeutic effects.
3) Ischemia/reperfusion-induced ALI
Gennai et al.56 used ex vivo perfused human lungs rejected for transplantation treated with 
MSC-derived EVs as a technique for rehabilitating marginal donor lungs.57 In the study, 
intravenous administration of MSC-derived EV improved alveolar fluid clearance rate in a 
dose dependent manner and decreased lung weight gain or pulmonary edema. MSC-derived 
EVs also increased nitric oxide level in the perfusate, which was associated with 
improvement of lung compliance and decrease in pulmonary artery pressure/resistance. 
Furthermore, MSC-derived EV reduced perfusate pH and lactate level, showing the 
metabolomic effects of MSC-derived EV. Finally, co-administration of CD44 neutralizing 
antibody with MSC-derived EVs abrogated the therapeutic effects on alveolar fluid 
clearance, lung weight, compliance, and pulmonary artery pressure/resistance, 
demonstrating the critical role of CD44 in the activity of the EVs.
4) Other lung disease models
There have been several investigations using MSC-derived EVs in the other lung diseases 
aside from ALI, which can help us understand the biological mechanisms of MSC-derived 
EVs in the pathophysiology of ALI. Cruz et al.58 demonstrated that MSC-derived EVs 
relieved allergic airway inflammation induced by repeated mucosal exposure of Aspergillus 
hyphal extract (AHE) in mice as a model of severe refractory asthma. Systemic 
administration of MSC-derived EVs isolated from both human and murine MSC suppressed 
the AHE-specific release of Th2- (IL-4 and IL-5) and Th17- (IL-17) mediated cytokines and 
boosted a counter-regulatory Th1 response (IFN-γ) in bronchoalveolar lavage fluid and in 
mixed lymphocyte culture. This study demonstrated that both syngeneic and xenogeneic 
administration of MSC-derived EV are effective in ameliorating airway hyper-reactivity and 
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lung inflammation by modulating Th2/Th17-mediated allergic airway inflammation. 
Blocking the release of both soluble factors and/or EVs from MSC completely abrogated the 
therapeutic effects of human MSC, but only partly inhibited those of murine MSC, which 
suggests that some different mechanisms exists between murine and human MSCs.
Lee et al.20 revealed in a mouse model of hypoxic pulmonary hypertension that MSC-
derived EV can partially reduce pulmonary hypertension specifically using the exosome 
fraction isolated by size-exclusion chromatography. The authors confirmed the 
morphological features (30 to 100 nm in diameter with biconcave shape) and the marker 
expressions (HSP90, Flotilin-1, CD63) of MSC derived exosomes. In their study, MSC-
derived exosomes inhibited the expression of pro-inflammatory mediators such as monocyte 
chemoattractant protein-1 and hypoxia-induced mitogenic factor after hypoxia, suppressed 
vascular remodeling, and thus prevented pulmonary hypertension. Signal transducer and 
activator of transcription 3 (STAT3) was activated following hypoxia in the lung, which was 
suppressed by the MSC-derived exosomes. Furthermore, the MSC-derived exosomes 
increased the levels of miR-204, a key microRNA which is decreased in human pulmonary 
hypertension. STAT3 activation is associated with respiratory epithelial inflammation and 
pro-proliferative miR-17 induction. In addition, STAT3 and miR-204 are in the STAT3-
miR-204-STAT3 feed-forward loop. Therefore, MSC-derived exosomes can alleviate 
pulmonary hypertension by suppressing STAT3 activation and interfering with the STAT3-
miR-204-STAT3 feed-forward loop.
More recently, Willis et al.59 demonstrated the role of MSC-derived exosomes in a model of 
bronchopulmonary dysplasia. The authors also used MSC-derived exosomes isolated by 
flotation on an iodixanol cushion (30– 150 nm in diameter, expressing CD9, CD63, and 
flotilin-1). Treatment with MSC-derived exosomes in newborn mice significantly improved 
lung architecture injured by hyperoxia. Additionally, MSC-derived exosomes improved 
pulmonary function and pulmonary hypertension. In lung transcriptome analysis, hyperoxia 
up-regulated genes related to the adaptive immune response, inflammatory response, and 
leukocyte mediated immunity. MSC-derived exosomes treatment blunted the hyperoxic up-
regulation of genes related to inflammation, adaptive immune responses, IFN-γ mediated-
signaling, granulocyte production, and cytokine production. This study confirmed that MSC-
derived exosomes regulated macrophage phenotype. In in vitro analysis with bone marrow 
derived macrophages, stimulation of classically activated (M1) macrophages with MSC-
derived exosomes suppressed the levels of TNFα, IL-6, and CCL5. Addition of MSC-
derived exosomes to alternatively activated (M2) macrophages enhanced Arg-1 expression, 
but suppressed CD206 induction. In experiments assessing lung macrophage in vivo, MSC-
derived exosomes suppressed the hyperoxic induction of CD40 (M1 phenotype marker) and 
CD206 (M2 phenotype marker).
CONCLUSIONS
Besides MSCs, EVs released from human MSCs have therapeutic properties in various pre-
clinical models of ALI. The therapeutic potency of MSC-derived EVs can be equivalent to 
those of MSC, and the mechanism of action of MSC may be also be recapitulated in MSC-
derived EVs. MSC-derived EVs can be an attractive alternative to MSCs when considering 
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the risk of iatrogenic tumor formation or of pulmonary embolism with IV administration of 
MSC. However, many questions will need to be addressed prior to any serious translation to 
clinical trials: 1) Standardized techniques to characterize and quantify EVs; 2) Appropriate 
assessments for potency to compare between MSC and MSC-derived EVs; 3) Whether MSC 
derived exosomes, microvesicles or both are more effective; and 4) Cost-effectiveness 
between the productions for MSC and MSC-derived EVs. Regardless, cell-based therapy 
with EVs has become a legitimate alternative to using live cells and should be studied 
further.
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Figure. Therapeutic potential of extracellular vesicles derived from mesenchymal stem cells in 
acute lung injury.
(A) In ALI models with various etiologies including lipopolysaccharide, Escherichia coli 
bacteria, and ischemia-reperfusion injury, administration of MSC-derived EVs was 
associated with the transfer of Ang-11 and KGF mRNA and possibly mitochondria from the 
EVs to the alveolar epithelium and endothelium, contributing in preservation of alveolar-
capillary permeability and improved alveolar fluid clearance. MSC-derived EVs also 
changed monocyte/macrophage towards an anti-inflammatory phenotype with increased 
phagocytic activity, which resulted in increased bacterial clearance. (B) In a model of 
hyperoxia-induced bronchopulmonary dysplasia, MSC-derived exosomes improved lung 
architecture and function through modulation of lung macrophage phenotype, suppressing 
the pro-inflammatory M1 and augmenting an anti-inflammatory M2-like state. In a model of 
hypoxia-induced pulmonary hypertension, MSC-derived exosomes also prevented vascular 
remodeling by suppressing the hypoxic induction of STAT3 and up-regulated miR-204 
levels, interfering with the STAT3-miR-204-STAT3 feed-forward loop. In a model of 
aspergillus hyphal extract-induced asthma, MSC-derived EVs mitigated Th2/Th17-mediated 
airway hyper-responsiveness by shifting the Th2/Th17 inflammatory response towards a 
counter-regulatory Th1 response. MSC, mesenchymal stem cell; EV, extracellular vesicle; 
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LPS, lipopolysaccharide; E. coli, Escherichia coli; ALI, acute lung injury; ARDS, acute 
respiratory distress syndrome; Ang-1, angiopoietin-1; KGF, keratinocyte growth factor; 
BPD, bronchopulmonary dysplasia; PH, pulmonary hypertension; STAT3, signal transducer 
and activator transcription 3; AHE, aspergillus hyphal extract.
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